Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma

Blood

Volumn 119, Issue 18, 2012, Pages 4115-4122

  Horwitz, Steven M ^a   Kim, Youn H ^b   Foss, Francine ^c   Zain, Jasmine M ^d   Myskowski, Patricia L ^a   Lechowicz, Mary Jo ^e   Fisher, David C ^f   Shustov, Andrei R ^g   Nancy L Bartlett, ^h   Maria L Delioukina, ⁱ   Tony Koutsoukos, ^j   Michael E Saunders, ^j   Owen A O'Connor, ^k   Madeleine Duvic, ^l  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b STANFORD CANCER INSTITUTE   (United States)

^c YALE CANCER CENTER   (United States)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^h WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ CEDARS SINAI MEDICAL CENTER   (United States)

^j Allos Therapeutics Inc   (United States)

^k New York Presbyterian Hospital Columbia University Medical Center   (United States)

^l University of Texas Health Science Center at Houston   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PRALATREXATE;

ADULT; ADVERSE OUTCOME; AGED; ANEMIA; ANOREXIA; ARTICLE; BLEEDING; BLOOD TOXICITY; BURNING SENSATION; CANCER RELAPSE; CANCER RESISTANCE; CUTANEOUS T CELL LYMPHOMA; DIARRHEA; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG TOLERABILITY; DYSPNEA; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HERPES ZOSTER; HUMAN; INFECTION; LARGE CELL LYMPHOMA; LEUKOPENIA; LIVER FUNCTION TEST; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYCOSIS FUNGOIDES; NEUTROPENIA; PRIORITY JOURNAL; PRURITUS; RASH; RECOMMENDED DRUG DOSE; SEZARY SYNDROME; SIDE EFFECT; SKIN DEFECT; STAPHYLOCOCCUS INFECTION; STOMATITIS; THROMBOCYTOPENIA; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEAKNESS;

EID: 84860775360     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-11-390211     Document Type: Article

References (35)

1. Willemze R, Meijer CJ. Primary cutaneous CD30-positive lymphoproliferative disorders. Hematol Oncol Clin North Am. 2003;17(6):1319- 1332. (Pubitemid 37523672)
2. Horwitz SM, Olsen EA, Duvic M, Porcu P, Kim YH. Review of the treatment of mycosis fungoides and Sezary syndrome: A stage-based approach. J Natl Compr Canc Netw. 2008;6(4):436-442. (Pubitemid 351642616)
3. Kim YH, Liu HL, Mraz-Gernhard S, Varghese A, Hoppe RT. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: Clinical prognostic factors and risk for disease progression. Arch Dermatol. 2003;139(7):857-866. (Pubitemid 36898920)
4. Kaye FJ, Bunn PA Jr, Steinberg SM, et al. A randomized trial comparing combination electronbeam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med. 1989;321(26):1784-1790. (Pubitemid 20015571)
5. Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007; 25(21):3109-3115. (Pubitemid 47218059)
6. Olsen E, Duvic M, Frankel A, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol. 2001;19(2):376-388. (Pubitemid 32112849)
7. Duvic M, Hymes K, Heald P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: Multinational phase II-III trial results. J Clin Oncol. 2001;19(9):2456-2471. (Pubitemid 32391217)
8. Duvic M, Martin AG, Kim Y, et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol. 2001;137(5):581-593. (Pubitemid 32458440)
9. Whittaker SJ, Demierre MF, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010;28(29):4485-4491.
10. Piekarz RL, Frye R, Turner M, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2009;27(32):5410-5417.
11. Prince HM, Duvic M, Martin A, et al. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2010;28(11):1870-1877.
12. Zinzani PL, Musuraca G, Tani M, et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25(27): 4293-4297. (Pubitemid 47548570)
13. Lundin J, Hagberg H, Repp R, et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood. 2003;101(11): 4267-4272. (Pubitemid 36857787)
14. Zackheim HS, Kashani-Sabet M, McMillan A. Low-dose methotrexate to treat mycosis fungoides: A retrospective study in 69 patients. J Am Acad Dermatol. 2003;49(5):873-878. (Pubitemid 37314876)
15. Olsen EA. Interferon in the treatment of cutaneous T-cell lymphoma. Dermatol Ther. 2003;16(4): 311-321. (Pubitemid 38044675)
16. Duvic M, Talpur R, Wen S, Kurzrock R, David CL, Apisarnthanarax N. Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. Clin Lymphoma Myeloma. 2006;7(1):51-58. (Pubitemid 44322770)
17. Zinzani PL, Baliva G, Magagnoli M, et al. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: Experience in 44 patients. J Clin Oncol. 2000;18(13):2603-2606. (Pubitemid 30432527)
18. Kurzrock R, Pilat S, Duvic M. Pentostatin therapy of T-cell lymphomas with cutaneous manifestations. J Clin Oncol. 1999;17(10):3117-3121. (Pubitemid 29470640)
19. Wollina U, Dummer R, Brockmeyer NH, et al. Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer. 2003;98(5):993-1001. (Pubitemid 37022100)
20. Foss FM. Evaluation of the pharmacokinetics, preclinical and clinical efficacy of pralatrexate for the treatment of T-cell lymphoma. Expert Opin Drug Metab Toxicol. 2011;7(9):1141-1152.
21. Wang ES, O'Connor O, She Y, Zelenetz AD, Sirotnak FM, Moore MA. Activity of a novel antifolate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. Leuk Lymphoma. 2003;44(6):1027-1035. (Pubitemid 36417003)
22. Sirotnak FM, DeGraw JI, Colwell WT, Piper JR. A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice. Cancer Chemother Pharmacol. 1998;42(4):313-318. (Pubitemid 28393849)
23. Krug LM, Ng KK, Kris mg, et al. Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate. Clin Cancer Res. 2000;6(9):3493-3498.
24. Azzoli CG, Patel JD, Krug LM, et al. Pralatrexate with vitamin supplementation in patients with previously treated, advanced non-small cell lung cancer: Safety and efficacy in a phase 1 trial. J Thorac Oncol. 2011;6(11):1915-1922.
25. Fury mg, Krug LM, Azzoli CG, et al. A phase I clinical pharmacologic study of pralatrexate in combination with probenecid in adults with advanced solid tumors. Cancer Chemother Pharmacol. 2006;57(5):671-677. (Pubitemid 43237853)
26. Krug LM, Azzoli CG, Kris mg, et al. 10-propargyl-10-deazaaminopterin: An antifolate with activity in patients with previously treated non-small cell lung cancer. Clin Cancer Res. 2003;9(6):2072-2078. (Pubitemid 36687627)
27. Krug LM, Heelan RT, Kris MG, Venkatraman E, Sirotnak FM. Phase II trial of pralatrexate (10-propargyl-10-deazaaminopterin, PDX) in patients with unresectable malignant pleural mesothelioma. J Thorac Oncol. 2007;2(4):317-320. (Pubitemid 47181715)
28. Azzoli CG, Krug LM, Gomez J, et al. A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumors. Clin Cancer Res. 2007;13(9):2692-2698. (Pubitemid 46788037)
29. O'Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: Results from the pivotal PROPEL study. J Clin Oncol. 2011;29(9):1182-1189.
30. Mould DR, Sweeney K, Duffull SB, et al. A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin's or Hodgkin's lymphoma. Clin Pharmacol Ther. 2009;86(2):190-196.
31. Horwitz SM, Vose JM, Advani R, et al. Pralatrexate and gemcitabine in patients with relapsed or refractory lymphoproliferative malignancies: Phase 1 results [abstract]. Blood (ASH Annual Meeting Abstracts). 2009:Abstract 1674.
32. O'Connor OA, Horwitz S, Hamlin P, et al. Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol. 2009;27(26): 4357-4364.
33. AJCC Cancer Staging Handbook. American Joint Committee on Cancer. 6th Ed. New York, NY: Springer; 2002.
34. Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007; 110(6):1713-1722. (Pubitemid 47443880)
35. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-586. (Pubitemid 350002966)